- JNJ dividends total $5.36 annually per share and yield about 2.02% at a share price near $265.58.
- Johnson & Johnson has raised its dividend for 64 consecutive years, supported by expected free cash flow approaching $21 billion.
- The stock’s near-2% yield is below its five-year average of 2.83% as the share price trades close to its 52-week high.
Dividend snapshot
JNJ pays a quarterly dividend of $1.34 per share, or $5.36 annually, equating to a forward yield of about 2.02% at a share price near $265.58. The yield tops the broader market and large-cap pharma averages but remains below JNJ’s five-year average yield of 2.83%.
The key attraction is consistency. JNJ has delivered 64 consecutive years of dividend increases, placing it among the market’s most established dividend-growth companies.
Its dividend has grown at roughly 4.0% annually over one year, 5.0% over five years, and 5.5% over 10 years. For an investor buying today, every 100 shares would generate about $536 in annual dividend income before taxes, assuming the current payout remains unchanged.
Cash flow supports the payout
JNJ’s capacity to sustain and raise its dividend remains the central positive for income investors. The company expects full-year free cash flow approaching $21 billion, while year-to-date free cash flow was approximately $8.7 billion.
Reported payout ratios range from about 49% of trailing earnings to 58.3%, depending on the calculation method. Either figure suggests a manageable commitment rather than an overstretched dividend.
Management has lifted its operating outlook, targeting roughly $100.6 billion in sales and adjusted operational EPS of $11.50 to $11.65. Analysts expect 2026 EPS growth of 7.41%, which could support another mid-single-digit dividend raise if execution holds.
JNJ’s Innovative Medicine and MedTech businesses provide diversified healthcare exposure, helping reduce dependence on any one product category or economic cycle.
Valuation limits current income appeal
JNJ trades near $266, close to its 52-week high of $281.07, with a trailing P/E ratio around 30.8. Its approximately 2% yield sits close to a two-year low and materially below its historical average because the share price has climbed faster than the dividend.
That makes JNJ dividends better suited to investors seeking rising income and portfolio stability than those needing immediate high cash flow. Higher-income alternatives can carry more interest-rate, leverage, or business-model risk.
Risks remain in focus
The key overhang remains talc litigation, including a proposed $5.5 billion ovarian-cancer settlement and roughly $3.7 billion in reserves. Regulatory changes, clinical-trial outcomes, drug-pricing pressure, and any restructuring of the MedTech portfolio also deserve monitoring.
JNJ remains a high-quality dividend-growth holding with strong cash generation, a remarkable payout record, and credible earnings support. At today’s elevated valuation and near-2% yield, dividend investors may want to build positions gradually or wait for market weakness.
